HIV infection and bone disease (Q30249771)

13 June 2017

1 reference

title

HIV infection and bone disease (English)

1 reference

13 June 2017

1 reference

J Compston

1

1 reference

13 June 2017

language of work or name

English

0 references

publication date

6 June 2016

1 reference

Journal of Internal Medicine

13 June 2017

published in

1 reference

13 June 2017

volume

280

1 reference

13 June 2017

issue

4

1 reference

13 June 2017

page(s)

350-358

1 reference

Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals

13 June 2017

cites work

1 reference

Increasing trends in HIV prevalence among people aged 50 years and older: evidence from estimates and survey data

21 January 2018

1 reference

Future challenges for clinical care of an ageing population infected with HIV: a modelling study

21 January 2018

1 reference

HIV infection and osteoporosis

21 January 2018

1 reference

Aging with HIV vs. HIV seroconversion at older age: a diverse population with distinct comorbidity profiles

21 January 2018

1 reference

Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy

21 January 2018

1 reference

Osteopenia in HIV-infected women prior to highly active antiretroviral therapy

21 January 2018

1 reference

Reduced bone density in HIV-infected women

21 January 2018

1 reference

Bone mass and mineral metabolism in HIV postmenopausal women

21 January 2018

1 reference

HIV infection and bone mineral density in middle-aged women

21 January 2018

1 reference

Osteopenia and osteoporosis in patients with HIV: a review of current concepts

21 January 2018

1 reference

Bone disease and HIV infection

21 January 2018

1 reference

Low Bone Mass in Behaviorally HIV-Infected Young Men on Antiretroviral Therapy: Adolescent Trials Network Study 021B

21 January 2018

1 reference

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

21 January 2018

1 reference

Bone mass, body composition and vitamin D status of ARV-naïve, urban, black South African women with HIV infection, stratified by CD₄ count.

21 January 2018

1 reference

Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans

21 January 2018

1 reference

Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

21 January 2018

1 reference

Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients

21 January 2018

1 reference

Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.

21 January 2018

1 reference

Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial

21 January 2018

1 reference

Longitudinal analysis of bone density in human immunodeficiency virus-infected women

21 January 2018

1 reference

Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

21 January 2018

1 reference

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

21 January 2018

1 reference

Continuous antiretroviral therapy decreases bone mineral density

21 January 2018

1 reference

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

21 January 2018

1 reference

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

21 January 2018

1 reference

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

21 January 2018

1 reference

Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia

21 January 2018

1 reference

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

21 January 2018

1 reference

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

21 January 2018

1 reference

Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir

21 January 2018

1 reference

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

21 January 2018

1 reference

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

21 January 2018

1 reference

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

21 January 2018

1 reference

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

21 January 2018

1 reference

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

21 January 2018

1 reference

Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.

21 January 2018

1 reference

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

Prominent Bone Loss Mediated by RANKL and IL-17 Produced by CD4 T Cells in TallyHo/JngJ Mice

21 January 2018

1 reference

Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection

21 January 2018

1 reference

Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study

21 January 2018

1 reference

Increased risk of fragility fractures among HIV infected compared to uninfected male veterans

21 January 2018

1 reference

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

21 January 2018

1 reference

Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection

21 January 2018

1 reference

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

21 January 2018

1 reference

Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study

21 January 2018

1 reference

Incident fractures in HIV-infected individuals: a systematic review and meta-analysis

21 January 2018

1 reference

Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection

21 January 2018

1 reference

Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients

21 January 2018

1 reference

Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection

21 January 2018

1 reference

DUAL-ENERGY X-RAY ABSORPTIOMETRY AND CALCULATED FRAX RISK SCORES MAY UNDERESTIMATE OSTEOPOROTIC FRACTURE RISK IN VITAMIN D-DEFICIENT VETERANS WITH HIV INFECTION.

21 January 2018

1 reference

Assessment of radiological vertebral fractures in HIV-infected patients: clinical implications and predictive factors.

21 January 2018

1 reference

Low bone mineral density and risk of incident fracture in HIV-infected adults

21 January 2018

1 reference

Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study

21 January 2018

1 reference

Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women

21 January 2018

1 reference

Trabecular and cortical microarchitecture in postmenopausal HIV-infected women

21 January 2018

1 reference

Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life

21 January 2018

1 reference

Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women

21 January 2018

1 reference

Brief Report: HIV Infection Is Associated With Worse Bone Material Properties, Independently of Bone Mineral Density.

21 January 2018

1 reference

Recommendations for evaluation and management of bone disease in HIV.

21 January 2018

1 reference

Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients

21 January 2018

1 reference

Teriparatide treatment of osteoporosis in an HIV-infected man: a case report and literature review

21 January 2018

1 reference

Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.

21 January 2018

1 reference

Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection

21 January 2018

1 reference

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.

21 January 2018

1 reference

Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial

21 January 2018

1 reference

Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.

21 January 2018

1 reference

A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis

21 January 2018

1 reference

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JOIM.12520

1 reference

13 June 2017

1 reference